Last $32.16 USD
Change Today -0.96 / -2.90%
Volume 1.1M
As of 8:10 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

cempra inc (CEMP) Snapshot

Open
$33.24
Previous Close
$33.12
Day High
$33.46
Day Low
$31.52
52 Week High
02/27/15 - $33.58
52 Week Low
04/15/14 - $8.10
Market Cap
1.4B
Average Volume 10 Days
846.0K
EPS TTM
$-1.80
Shares Outstanding
43.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CEMPRA INC (CEMP)

cempra inc (CEMP) Related Businessweek News

No Related Businessweek News Found

cempra inc (CEMP) Details

Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases in North America. Its two lead product candidates include Solithromycin (CEM-101), which is in a Phase III clinical trial for community-acquired bacterial pneumonia (CABP); and TAKSTA (CEM-102) that is in a Phase II clinical trial for prosthetic joint infections. The company also focuses on using its series of proprietary lead compounds from its novel macrolide library for uses, such as the treatment of chronic inflammatory diseases, endocrine diseases, and gastric motility disorders. It has collaborative research and development and license agreement with Optimer Pharmaceuticals, Inc. The company was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012. Cempra, Inc. was founded in 2005 and is headquartered in Chapel Hill, North Carolina.

55 Employees
Last Reported Date: 02/26/15
Founded in 2005

cempra inc (CEMP) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $447.2K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $292.6K
Compensation as of Fiscal Year 2013.

cempra inc (CEMP) Key Developments

Cempra, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Cempra, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenues of $2,470,000 compared to revenues of $2,073,000 for the same period a year ago. Loss from operations was $16,264,000 compared to $16,148,000 last year. Net loss and comprehensive loss was $16,895,000 compared to $16,830,000 last year. Net loss attributable to common shareholders was $16,895,000 or $0.46 per basic and diluted share compared to $16,830,000 or $0.51 per basic and diluted share last year. Net loss has historically been driven largely by R&D spend, some of which is offset by revenue received under BARDA contract. For the year, the company reported revenues of $15,216,000 compared to revenues of $7,813,000 for the same period a year ago. Loss from operations was $59,400,000 compared to $42,920,000 last year. Net loss and comprehensive loss was $61,649,000 compared to $45,035,000 last year. Net loss attributable to common shareholders was $61,649,000 or $1.81 per basic and diluted share compared to $45,035,000 or $1.53 per basic and diluted share last year.

Cempra, Inc. to Report Q4, 2014 Results on Feb 25, 2015

Cempra, Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Feb 25, 2015

Cempra, Inc., Q4 2014 Earnings Call, Feb 25, 2015

Cempra, Inc., Q4 2014 Earnings Call, Feb 25, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CEMP:US $32.16 USD -0.96

CEMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CEMP.
View Industry Companies
 

Industry Analysis

CEMP

Industry Average

Valuation CEMP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 79.4x
Price/Book 20.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 87.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEMPRA INC, please visit www.cempra.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.